Aripiprazole, Ziprasidone and Quetiapine in the treatment of first-episode nonaffective psychosis: A 12-week randomized, flexible-dose, open-label trial

Schizophrenia Research

Volumn 147, Issue 2-3, 2013, Pages 375-382

  Crespo Facorro, Benedicto ^a,b   Ortiz García de la Foz, Victor ^a,b   Mata, Ignacio ^a,b   Ayesa Arriola, Rosa ^a,b   Suarez Pinilla, Paula ^a   Valdizan, Elsa M ^b,d   Vázquez Barquero, José Luis ^a,b   Pérez Iglesias, Rocío ^b,c  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF CANTABRIA   (Spain)

Author keywords

Adverse effects; Antipsychotic agents; Psychotherapeutic processes; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; QUETIAPINE; ZIPRASIDONE;

ADOLESCENT; ADULT; AKATHISIA; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SLEEP TIME; SOMNOLENCE;

ADULT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; DIBENZOTHIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; OUTCOME ASSESSMENT (HEALTH CARE); PIPERAZINES; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; QUINOLONES; RETROSPECTIVE STUDIES; THIAZOLES; TIME FACTORS; YOUNG ADULT;

EID: 84878971779     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2013.04.014     Document Type: Article

References (40)

1. Addington D., Addington J., Maticka-Tyndale E. Assessing depression in schizophrenia: the Calgary Depression Scale. Br. J. Psychiatry Suppl. 1993, (22):39-44.
2. Andreasen N.C. Scale for the Assessment of Negative symptoms (SANS) 1983, University of Iowa, Iowa City.
3. Andreasen N.C. Scale for the Assessment of Positive Symptoms (SAPS) 1984, University of Iowa, Iowa City.
4. Barnes T.R. A rating scale for drug-induced akathisia. Br. J. Psychiatry 1989, 154:672-676.
5. Basson B.R., Kinon B.J., Taylor C.C., Szymanski K.A., Gilmore J.A., Tollefson G.D. Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. J. Clin. Psychiatry 2001, 62(4):231-238.
6. Crespo-Facorro B., Perez-Iglesias R., Ramirez-Bonilla M., Martinez-Garcia O., Llorca J., Luis Vazquez-Barquero J. A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis. J. Clin. Psychiatry 2006, 67(10):1511-1521.
7. Crespo-Facorro B., Perez-Iglesias R., Mata I., Ramirez-Bonilla M., Martinez-Garcia O., Pardo-Garcia G., Caseiro O., Pelayo-Teran J.M., Vazquez-Barquero J.L. Effectiveness of haloperidol, risperidone and olanzapine in the treatment of first-episode non-affective psychosis: results of a randomized, flexible-dose, open-label 1-year follow-up comparison. J. Psychopharmacol. 2011, 25(6):744-754.
8. Crespo-Facorro B., Perez-Iglesias R., Mata I., Martinez-Garcia O., Ortiz V., Pelayo-Teran J.M., Valdizan E., Vazquez-Barquero J.L. Long-term (3-year) effectiveness of haloperidol, risperidone and olanzapine: results of a randomized, flexible-dose, open-label comparison in first-episode nonaffective psychosis. Psychopharmacology (Berl) 2012, 219(1):225-233.
9. Crespo-Facorro B., Perez-Iglesias R., Mata I., Ortiz-Garcia de la Foz V., Martinez-Garcia O., Valdizan E., Vazquez-Barquero J.L. Aripiprazole, Ziprasidone and Quetiapine in the treatment of first-episode nonaffective psychosis: results of a 6-week, randomized, flexible-dose, open-label comparison. J. Clin. Psychopharmacol. 2013, 33(2):215-220.
10. Emsley R.A. Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Risperidone working group. Schizophr. Bull. 1999, 25(4):721-729.
11. First M.B., Spitzer R.L., Gibbon M., William J.B. Structured Clinical Interview for DSM-IV-TR Axis I Disorders-Non-patient Edition 2001, Biometrics Research Department, New York.
12. Glick I.D., Correll C.U., Altamura A.C., Marder S.R., Csernansky J.G., Weiden P.J., Leucht S., Davis J.M. Mid-term and long-term efficacy and effectiveness of antipsychotic medications for schizophrenia: a data-driven, personalized clinical approach. J. Clin. Psychiatry 2011, 72(12):1616-1627.
13. Green A.I., Lieberman J.A., Hamer R.M., Glick I.D., Gur R.E., Kahn R.S., McEvoy J.P., Perkins D.O., Rothschild A.J., Sharma T., Tohen M.F., Woolson S., Zipursky R.B. Olanzapine and haloperidol in first episode psychosis: two-year data. Schizophr. Res. 2006, 86(1-3):234-243.
14. Grootens K.P., van Veelen N.M., Peuskens J., Sabbe B.G., Thys E., Buitelaar J.K., Verkes R.J., Kahn R.S. Ziprasidone vs olanzapine in recent-onset schizophrenia and schizoaffective disorder: results of an 8-week double-blind randomized controlled trial. Schizophr. Bull. 2011, 37(2):352-361.
15. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education, and Welfare Publication ADM 76338 1976, 217-222. National Institute of Mental Health, Washington, DC.
16. Johnsen E., Jorgensen H.A. Effectiveness of second generation antipsychotics: a systematic review of randomized trials. BMC Psychiatry 2008, 8:31.
17. Kahn R.S., Fleischhacker W.W., Boter H., Davidson M., Vergouwe Y., Keet I.P., Gheorghe M.D., Rybakowski J.K., Galderisi S., Libiger J., Hummer M., Dollfus S., Lopez-Ibor J.J., Hranov L.G., Gaebel W., Peuskens J., Lindefors N., Riecher-Rossler A., Grobbee D.E. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008, 371(9618):1085-1097.
18. Kasper S., Tauscher J., Heiden A. Quetiapine: efficacy and tolerability in schizophrenia. Eur. Neuropsychopharmacol. 2001, 11(Suppl. 4). (S405-13).
19. Kerwin R., Millet B., Herman E., Banki C.M., Lublin H., Pans M., Hanssens L., L'Italien G., McQuade R.D., Beuzen J.N. A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study. Eur. Psychiatry 2007, 22(7):433-443.
20. Komossa K., Rummel-Kluge C., Schmid F., Hunger H., Schwarz S., El-Sayeh H.G., Kissling W., Leucht S. Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst. Rev. 2009, (4):CD006569.
21. Komossa K., Rummel-Kluge C., Schmid F., Hunger H., Schwarz S., Srisurapanont M., Kissling W., Leucht S. Quetiapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst. Rev. 2010, (1):CD006625.
22. Lee K.U., Jeon Y.W., Lee H.K., Jun T.Y. Efficacy and safety of quetiapine for depressive symptoms in patients with schizophrenia. Hum. Psychopharmacol. 2009, 24(6):447-452.
23. Leucht S., Komossa K., Rummel-Kluge C., Corves C., Hunger H., Schmid F., Asenjo Lobos C., Schwarz S., Davis J.M. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am. J. Psychiatry 2009, 166(2):152-163.
24. Lieberman J.A. Atypical antipsychotic drugs as a first-line treatment of schizophrenia: a rationale and hypothesis. J. Clin. Psychiatry 1996, 57(Suppl. 11):68-71.
25. Lieberman J.A., Tollefson G., Tohen M., Green A.I., Gur R.E., Kahn R., McEvoy J., Perkins D., Sharma T., Zipursky R., Wei H., Hamer R.M. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am. J. Psychiatry 2003, 160(8):1396-1404.
26. Lingjaerde O., Ahlfors U.G., Bech P., Dencker S.J., Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr. Scand. Suppl. 1987, 334:1-100.
27. McEvoy J.P., Hogarty G.E., Steingard S. Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose. Arch. Gen. Psychiatry 1991, 48(8):739-745.
28. McEvoy J.P., Lieberman J.A., Perkins D.O., Hamer R.M., Gu H., Lazarus A., Sweitzer D., Olexy C., Weiden P., Strakowski S.D. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am. J. Psychiatry 2007, 164(7):1050-1060.
29. Overall J.E., Gorham D.R. The brief psychiatric rating scale. Psychol. Rep. 1962, 10:799-812.
30. Pelayo-Teran J.M., Perez-Iglesias R., Ramirez-Bonilla M., Gonzalez-Blanch C., Martinez-Garcia O., Pardo-Garcia G., Rodriguez-Sanchez J.M., Roiz-Santianez R., Tordesillas-Gutierrez D., Mata I., Vazquez-Barquero J.L., Crespo-Facorro B. Epidemiological factors associated with treated incidence of first-episode non-affective psychosis in Cantabria: insights from the Clinical Programme on Early Phases of Psychosis. Early Interv. Psychiatry 2008, 2(3):178-187.
31. Rummel-Kluge C., Komossa K., Schwarz S., Hunger H., Schmid F., Kissling W., Davis J.M., Leucht S. Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons. Schizophr. Bull. 2012, 38(1):167-177.
32. Sajatovic M., Mullen J.A., Sweitzer D.E. Efficacy of quetiapine and risperidone against depressive symptoms in outpatients with psychosis. J. Clin. Psychiatry 2002, 63(12):1156-1163.
33. Sanger T.M., Lieberman J.A., Tohen M., Grundy S., Beasley C., Tollefson G.D. Olanzapine versus haloperidol treatment in first-episode psychosis. Am. J. Psychiatry 1999, 156(1):79-87.
34. Simpson G.M., Angus J.W. A rating scale for extrapyramidal side effects. Acta Psychiatr. Scand. Suppl. 1970, 212:11-19.
35. Small J.G., Hirsch S.R., Arvanitis L.A., Miller B.G., Link C.G. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel study group. Arch. Gen. Psychiatry 1997, 54(6):549-557.
36. Sparshatt A., Jones S., Taylor D. Quetiapine: dose-response relationship in schizophrenia. CNS Drugs 2008, 22(1):49-68. (discussion 69-72).
37. Sparshatt A., Taylor D., Patel M.X., Kapur S. Relationship between daily dose, plasma concentrations, dopamine receptor occupancy, and clinical response to quetiapine: a review. J. Clin. Psychiatry 2011, 72(8):1108-1123.
38. Tandon R., Belmaker R.H., Gattaz W.F., Lopez-Ibor J.J., Okasha A., Singh B., Stein D.J., Olie J.P., Fleischhacker W.W., Moeller H.J. World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr. Res. 2008, 100(1-3):20-38.
39. Tauscher-Wisniewski S., Kapur S., Tauscher J., Jones C., Daskalakis Z.J., Papatheodorou G., Epstein I., Christensen B.K., Zipursky R.B. Quetiapine: an effective antipsychotic in first-episode schizophrenia despite only transiently high dopamine-2 receptor blockade. J. Clin. Psychiatry 2002, 63(11):992-997.
40. Young R.C., Biggs J.T., Ziegler V.E., Meyer D.A. A rating scale for mania: reliability, validity and sensitivity. Br. J. Psychiatry 1978, 133:429-435.